BioSpace News Archive

A recent study published in CA: A Cancer Journal for Clinicians, a peer-review journal of the American Cancer Society, links excess body weight to approximately 4 percent of cancers worldwide.

Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Orchard Therapeutics is expanding its physical footprint in California. The U.K.-based company signed a long-term lease to build out a gene therapy manufacturing facility in Fremont, Calif. The 150,000-square-foot facility will add to the company’s presence in the Bay Area.

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today announces that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of Feraccru®

As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.

With more than 15 million people in need of anticoagulants around the world, AMAG sees a significant future for ciraparantag.

According to Stephanie Moore, author of The Gifted Journey, you should have a “personal board of directors” to bounce ideas off of and discuss your goals with. You could include trusted colleagues, mentors, and career coaches as part of your personal board.

Merck and Co. inked a research collaboration deal with Instituto Butantan, based in Sao Paulo, Brazil, to develop vaccines against dengue virus disease.

More than 44 percent of home health providers will see a decrease in reimbursement under the Patient Driven Groupings Model